Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes

Melanie C. Dispenza, Bruce Scott Bochner

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Purpose of Review: Hypereosinophilic syndrome (HES) is characterized by persistent hypereosinophilia associated with end-organ damage. As our understanding of the pathogenesis of various forms of HES broadens, so does our ability to tailor steroid-sparing therapies for each subtype. The purpose of this review is to summarize recent literature related to the etiology, diagnosis, and management of HES. Recent Findings: Mutations involved in subsets of HES can guide the choice of tyrosine kinase inhibitors beyond just imatinib. Several biologics that target interleukin-5 or its receptor have shown beneficial and selective eosinophil-reducing effects in clinical trials for asthma and other disorders including HES. Early clinical data with emerging therapies such as dexpramipexole and anti-Siglec-8 antibody show promise, but need to be confirmed in randomized trials. Summary: Several new biologics and tyrosine kinase inhibitors have been shown to lower eosinophil numbers, but more randomized trials are needed to confirm efficacy in HES.

Original languageEnglish (US)
Pages (from-to)191-201
Number of pages11
JournalCurrent Hematologic Malignancy Reports
Volume13
Issue number3
DOIs
StatePublished - Jun 1 2018

Fingerprint

Hypereosinophilic Syndrome
Biological Products
Eosinophils
Protein-Tyrosine Kinases
Sialic Acid Binding Immunoglobulin-like Lectins
Interleukin-5
Asthma
Steroids
Clinical Trials
Mutation
Antibodies
Therapeutics

Keywords

  • Biologic
  • Dexpramipexole
  • Hypereosinophilic syndrome
  • IL-5
  • Siglec-8
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{9e122943522348d89597ffcb637bf80d,
title = "Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes",
abstract = "Purpose of Review: Hypereosinophilic syndrome (HES) is characterized by persistent hypereosinophilia associated with end-organ damage. As our understanding of the pathogenesis of various forms of HES broadens, so does our ability to tailor steroid-sparing therapies for each subtype. The purpose of this review is to summarize recent literature related to the etiology, diagnosis, and management of HES. Recent Findings: Mutations involved in subsets of HES can guide the choice of tyrosine kinase inhibitors beyond just imatinib. Several biologics that target interleukin-5 or its receptor have shown beneficial and selective eosinophil-reducing effects in clinical trials for asthma and other disorders including HES. Early clinical data with emerging therapies such as dexpramipexole and anti-Siglec-8 antibody show promise, but need to be confirmed in randomized trials. Summary: Several new biologics and tyrosine kinase inhibitors have been shown to lower eosinophil numbers, but more randomized trials are needed to confirm efficacy in HES.",
keywords = "Biologic, Dexpramipexole, Hypereosinophilic syndrome, IL-5, Siglec-8, Tyrosine kinase inhibitor",
author = "Dispenza, {Melanie C.} and Bochner, {Bruce Scott}",
year = "2018",
month = "6",
day = "1",
doi = "10.1007/s11899-018-0448-8",
language = "English (US)",
volume = "13",
pages = "191--201",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "3",

}

Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes. / Dispenza, Melanie C.; Bochner, Bruce Scott.

In: Current Hematologic Malignancy Reports, Vol. 13, No. 3, 01.06.2018, p. 191-201.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes

AU - Dispenza, Melanie C.

AU - Bochner, Bruce Scott

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Purpose of Review: Hypereosinophilic syndrome (HES) is characterized by persistent hypereosinophilia associated with end-organ damage. As our understanding of the pathogenesis of various forms of HES broadens, so does our ability to tailor steroid-sparing therapies for each subtype. The purpose of this review is to summarize recent literature related to the etiology, diagnosis, and management of HES. Recent Findings: Mutations involved in subsets of HES can guide the choice of tyrosine kinase inhibitors beyond just imatinib. Several biologics that target interleukin-5 or its receptor have shown beneficial and selective eosinophil-reducing effects in clinical trials for asthma and other disorders including HES. Early clinical data with emerging therapies such as dexpramipexole and anti-Siglec-8 antibody show promise, but need to be confirmed in randomized trials. Summary: Several new biologics and tyrosine kinase inhibitors have been shown to lower eosinophil numbers, but more randomized trials are needed to confirm efficacy in HES.

AB - Purpose of Review: Hypereosinophilic syndrome (HES) is characterized by persistent hypereosinophilia associated with end-organ damage. As our understanding of the pathogenesis of various forms of HES broadens, so does our ability to tailor steroid-sparing therapies for each subtype. The purpose of this review is to summarize recent literature related to the etiology, diagnosis, and management of HES. Recent Findings: Mutations involved in subsets of HES can guide the choice of tyrosine kinase inhibitors beyond just imatinib. Several biologics that target interleukin-5 or its receptor have shown beneficial and selective eosinophil-reducing effects in clinical trials for asthma and other disorders including HES. Early clinical data with emerging therapies such as dexpramipexole and anti-Siglec-8 antibody show promise, but need to be confirmed in randomized trials. Summary: Several new biologics and tyrosine kinase inhibitors have been shown to lower eosinophil numbers, but more randomized trials are needed to confirm efficacy in HES.

KW - Biologic

KW - Dexpramipexole

KW - Hypereosinophilic syndrome

KW - IL-5

KW - Siglec-8

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85045760287&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045760287&partnerID=8YFLogxK

U2 - 10.1007/s11899-018-0448-8

DO - 10.1007/s11899-018-0448-8

M3 - Review article

VL - 13

SP - 191

EP - 201

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 3

ER -